benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)- profile

ID Source	ID
PubMed CID	9818903
CHEMBL ID	351231
SCHEMBL ID	118976
MeSH ID	M0480813

Synonym
abt 239
gtpl1218
4-[2-[2-[(2r)-2-methylpyrrolidin-1-yl]ethyl]-1-benzofuran-5-yl]benzonitrile
abt239
abt-239
(r)-4-(2-(2-(2-methylpyrrolidin-1-yl)ethyl)benzofuran-5-yl)benzonitrile
4-{2-[2-((r)-2-methyl-pyrrolidin-1-yl)-ethyl]-benzofuran-5-yl}-benzonitrile
bdbm50139391
CHEMBL351231 ,
460746-46-7
benzonitrile, 4-[2-[2-[(2r)-2-methyl-1-pyrrolidinyl]ethyl]-5-benzofuranyl]-
unii-86h6b395pi
(r)-4-(2-(2-(2-methyl-1-pyrrolidinyl)ethyl)-1-benzofuran-5-yl)benzonitrile
86h6b395pi ,
benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-
4-(2-(2-(2-methyl-1-pyrrolidinyl)ethyl)-1-benzofuran-5-yl)benzonitrile
AKOS015891396
(r)-4-(2-(2-(2-methylpyrrolidinyl)ethyl)benzofuran-5-yl)benzonitrile
SCHEMBL118976
4-(2-{2-[(2r)-2-methylpyrrolidinyl]ethyl}-1-benzofuran-5-yl)benzonitrile
4-(2-{2-[(2r)-2-methyl-1-pyrrolidinyl]ethyl}-1-benzofuran-5-yl)benzonitrile
KFHYZKCRXNRKRC-MRXNPFEDSA-N
HY-12195
DTXSID00196710
CS-5904
NCGC00386570-01
4-(2-{2-[(2r)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile
Q4650421
Z1816526082
abt-239 (tartrate)
D94991
4-(2-{2-[(2r)-2-methylpyrrolidin-1-yl]ethyl}-
benzofuran-5-yl)benzonitrile
AS-76470

Excerpt	Reference	Relevance
" As ciproxifan and thioperamide are inhibitors of cytochrome P450 enzymes, responsible for metabolizing risperidone and haloperidol, the possibility that the augmentation of antipsychotics by imidazoles resulted from drug-drug interactions was tested."	( Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Ballard, ME; Cowart, M; Decker, MW; Esbenshade, TA; Faghih, R; Fox, GB; Hancock, AA; Pan, L; Roberts, S; Rueter, LE; Zhang, M, 2005)	0.33

Excerpt	Reference	Relevance
" ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t1/2 values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%."	( Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. Bennani, YL; Cowart, MD; Denny, LI; Esbenshade, TA; Fox, GB; Hancock, AA; Kang, CH; Krueger, KM; Marsh, K; Miller, TR; Pan, L; Sullivan, JP; Wetter, J; Witte, DG; Yao, BB, 2005)	0.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" Efficacy in this model was maintained for 3 to 6 h and following repeated dosing with ABT-239."	( Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 re Ballard, ME; Bennani, YL; Bitner, RS; Browman, KE; Buckley, MJ; Cowart, MD; Decker, MW; Drescher, KU; Esbenshade, TA; Faghih, R; Fox, GB; Hancock, AA; Komater, VA; Krueger, KM; Lemaire, M; Marsh, K; Miner, H; Pan, JB; Porsolt, RD; Radek, RJ; Rueter, LE; Sullivan, JP; Wetter, J; Yao, BB; Zhang, M, 2005)	0.33

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 2D6	Homo sapiens (human)	Potency	13.4504	0.0010	8.3798	61.1304	AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	1.6000	0.0009	1.9014	10.0000	AID616657
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	Ki	0.4000	0.0021	1.8407	10.0000	AID483431
Histamine H3 receptor	Rattus norvegicus (Norway rat)	Ki	0.0040	0.0001	0.2963	8.5110	AID239562; AID239987; AID254439; AID302561; AID302564; AID305749; AID421583; AID483430; AID611518; AID622486; AID692493; AID89566; AID89863
Histamine H3 receptor	Homo sapiens (human)	IC50 (µMol)	0.0006	0.0005	0.4668	5.9000	AID389212
Histamine H3 receptor	Homo sapiens (human)	Ki	0.0017	0.0001	0.3399	8.5110	AID239591; AID239988; AID254441; AID290795; AID302560; AID305748; AID341508; AID375418; AID421582; AID483429; AID599203; AID611517; AID616658; AID622483; AID692494; AID86462; AID86612
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histamine H3 receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0174	0.0020	1.5592	6.2000	AID302566
Histamine H3 receptor	Homo sapiens (human)	EC50 (µMol)	0.0013	0.0000	0.0947	3.1623	AID302565
Histamine H3 receptor	Homo sapiens (human)	Kd	0.0129	0.0001	0.0138	0.0631	AID599205
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histamine H3 receptor	Homo sapiens (human)	Kb	0.0072	0.0002	0.2097	2.0000	AID302562; AID302563
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
neurotransmitter secretion	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Histamine H3 receptor	Homo sapiens (human)
chemical synaptic transmission	Histamine H3 receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
histamine receptor activity	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Histamine H3 receptor	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Histamine H3 receptor	Homo sapiens (human)
presynapse	Histamine H3 receptor	Homo sapiens (human)
plasma membrane	Histamine H3 receptor	Homo sapiens (human)
synapse	Histamine H3 receptor	Homo sapiens (human)
dendrite	Histamine H3 receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (117)

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID616659	Lipophilicity, log D of the compound	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity.
AID302569	Clearance in rat at 1 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302562	Antagonist activity at human histamine H3 receptor expressed with Galphaq/i5 in HEL239 cells assessed as reduction of RAMH-induced intracellular calcium	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID290795	Binding affinity to human histamine H3 receptor	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	A new class of histamine H3 receptor antagonists derived from ligand based design.
AID616658	Displacement of [125I]Iodoproxyfan from human recombinant histamine H3 receptor by Competitive binding assay	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity.
AID253633	Area under plasma concentration curve of the compound upon p.o. dose of 1 mg/kg in rats	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID302575	Protein binding in dog plasma	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID622483	Displacement of [3H]-NAMH from human histamine H3 receptor expressed in CHO cells	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.
AID483431	Displacement of [3H]dofetilide from human ERG expressed in HEK293 cells	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	In vitro studies on a class of quinoline containing histamine H3 antagonists.
AID236518	Clearance was observed in monkey after intravenous administration of 1-5 mg/kg	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID389212	Antagonist activity at human cloned histamine H3 receptor expressed in CHO-K1 cells assessed as inhibition of R-alpha-methylhistamine-induced [35S]GTPgammaS binding	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.
AID237276	Half life was observed in monkey after intravenous administration of 3-5 mg/kg; (n=3)	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID622486	Displacement of [3H]-NAMH from rat histamine H3 receptor expressed in CHO cells	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	Synthesis and structure-activity relationships of 4,5-fused pyridazinones as histamine H₃ receptor antagonists.
AID341508	Displacement of [3H]RAMH from human histamine H3 receptor expressed in CHO cells	2008	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15	Refinement of histamine H3 ligands pharmacophore model leads to a new class of potent and selective naphthalene inverse agonists.
AID237264	Half life was observed in rat after intravenous administration of 3-5 mg/kg; (n=3)	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305748	Displacement of [3H]N-alpha-methylhistamine from human cloned histamine H3 receptor expressed in C6 cells	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID237554	Volume of distribution was observed in rat after intravenous administration of 1-5 mg/kg	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID239988	In vitro binding affinity was determined as displacement of [3H]N-R-methylhistamine from C6 cell membranes expressing human histamine H3 receptor	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID302572	Ratio of drug level in brain to blood in mouse at 1 mg/kg, ip	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID86612	Binding potency was determined by displacement of [3H]N-alpha-methyl histamine from cloned human histamine H3 receptor expressed in C6 cells	2004	Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3	A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.
AID611518	Displacement of [3H]NAMH from rat histamine H3 receptor expressed in CHO cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID692497	Oral bioavailability in monkey at 1 mg/kg	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Histamine H3 receptor as a drug discovery target.
AID611517	Displacement of [3H]NAMH from human histamine H3 receptor expressed in CHO cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID302560	Displacement of [3H]-N-alpha methyl histamine from human H3 receptor expressed in C6 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302574	Ratio of drug level in brain to blood in rat at 1 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID239591	In vitro binding affinity was determined as displacement of [3H]N-R-methylhistamine from C6 cell membranes expressing human histamine H3 receptor	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID780100	Awakening activity in rat assessed as increased wakefulness at 10 mg/kg, po after 3 to 4 hrs	2013	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22	Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
AID89863	Binding potency was determined by displacement of [3H]N-alpha-methyl histamine from histamine H3 receptor of rat cortical membranes	2004	Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3	A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.
AID237553	Volume of distribution was observed in dog after intravenous administration of 1-5 mg/kg	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305753	Clearance in rat brain at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID305750	Half life in rat at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID236516	Clearance was observed in dog after intravenous administration of 1-5 mg/kg	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID599203	Displacement of [3H]N-alpha-methylhistamine from human histamine H3 receptor expressed in SK-N-MC cells	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists.
AID302563	Antagonist activity at human histamine H3 receptor expressed in HEK239 cells assessed as inhibition of RAMH-stimulated [35S]GTP-gamma-S binding	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID244036	Inhibition of CYP1A2 at 20 uM assessed by effect on rate of oxidation of phenacetin O-deethylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID253632	Area under plasma concentration curve of the compound upon i.v. dose of 1 mg/kg in rats	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID599205	Antagonist activity at human histamine H3 receptor expressed in SK-N-MC cells assessed as inhibition of forskolin stimulated cAMP accumulation after 6 hrs	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Heterocyclic replacement of the central phenyl core of diamine-based histamine H3 receptor antagonists.
AID611522	Bioavailability in fasted Sprague-Dawley rat at 1 mg/kg, iv after 6 to 24 hrs by LC-MS/MS analysis	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID305754	Cmax in rat at 1 mg/kg, po	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID246006	Lowest dose to induce CNS side effects was assessed in a general behavioral screen in rats	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244034	Inhibition of CYP3A4 at 2 uM assessed by effect on rate of oxidation of terfenadine hydroxylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244057	Inhibition of CYP2D6 at 20 uM assessed by effect on rate of oxidation of dextromethorphan O-demethylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID692495	Oral bioavailability in rat at 1 mg/kg	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Histamine H3 receptor as a drug discovery target.
AID237263	Half life was observed in dog after intravenous administration of 3-5 mg/kg; (n=3)	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305749	Displacement of [3H]N-alpha-methylhistamine from histamine H3 receptor in rat cortical membranes	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID239987	In vitro binding affinity was determined as displacement of [3H]N-R-methylhistamine from C6 cell membranes expressing rat histamine H3 receptor	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID236099	Bioavailability in dog (dose 1-5 mg/kg i.v.)	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305757	Oral bioavailability in rat at 1 mg/kg	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID302578	Protein binding in rat plasma	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID305756	AUC (0 to infinity) in rat at 1 mg/kg, po	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID616657	Displacement of [3H]dofetilide from human recombinant ERG by Competitive binding assay	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	Novel and highly potent histamine H3 receptor ligands. Part 1: withdrawing of hERG activity.
AID239893	Tested for its ability to block human histamine H3 receptor activation by the agonist R-alpha-methyl histamine in a [Ca2+] flux assay	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID302564	Antagonist activity at rat histamine H3 receptor expressed in HEK239 cells assessed as inhibition of RAMH-stimulated [35S]GTP-gamma-S binding	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID237820	Concentration in brain of rats after 1 hr of intravenous administration	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244029	Inhibition of CYP2A6 at 2 uM, assessed by effect on rate of oxidation of coumarin 7-hydroxylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID692496	Oral bioavailability in dog at 1 mg/kg	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Histamine H3 receptor as a drug discovery target.
AID246008	Tested for their ability to enhance learning in the rat pups using inhibitory avoidance acquisition model	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305752	AUC (0 to infinity) in rat at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID421582	Displacement of [3H]N-alpha methyl histamine from human cloned histamine H3 receptor expressed in C6 cells	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
AID244037	Inhibition of CYP2C9 at 20 uM assessed by its effect on rate of oxidation of Tolbutamide hydroxylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID421583	Displacement of [3H]N-alpha methyl histamine from rat cortical membrane histamine H3 receptor	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
AID236517	Clearance was observed in rat after intravenous administration of 1-5 mg/kg	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID302573	Drug level in rat brain at 1 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302567	Half life in rat at 1 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302570	Oral bioavailability in rat at 1 mg/kg	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID244033	Inhibition of CYP2C9 at 2 uM assessed by effect on rate of oxidation of Tolbutamide hydroxylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244032	Inhibition of CYP2A6 at 20 uM assessed by effect on rate of oxidation of coumarin 7-hydroxylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID611525	Ratio of drug uptake in brain to plasma of fasted Sprague-Dawley rat at 1 mg/kg, iv after 6 to 24 hrs by LC-MS/MS analysis	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID89566	Binding potency was determined by displacement of [3H]N-alpha-methyl histamine from histamine H3 receptor of rat cortical membranes	2004	Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3	A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.
AID305758	Ratio of drug level in brain to plasma in rat at 5 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID302577	Protein binding in monkey plasma	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID237555	Volume of distribution was observed in monkey after intravenous administration of 1-5 mg/kg	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305755	Half life in rat at 1 mg/kg, po	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID302571	Drug level in mouse brain at 1 mg/kg, ip	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302566	Agonist activity at rat histamine H3 receptor expressed in HEK239 cells assessed as reduction of basal [35S]GTP-gamma-S binding	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID692493	Binding affinity to rat cortical histamine H3 receptor	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Histamine H3 receptor as a drug discovery target.
AID244047	Inhibition of CYP2E1 at 20 uM assessed by effect on rate of oxidation of chlorzoxazone 6-hydroxylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID611520	Terminal half life in fasted Sprague-Dawley rat at 1 mg/kg, iv after 6 to 24 hrs by LC-MS/MS analysis	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID302561	Displacement of [3H]-N-alpha methyl histamine from rat H3 receptor expressed in C6 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID86462	Binding potency was determined by displacement of [3H]N-alpha-methyl histamine from cloned human histamine H3 receptor expressed in C6 cells	2004	Bioorganic & medicinal chemistry letters, Feb-09, Volume: 14, Issue:3	A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.
AID244052	Inhibition of CYP2C19 at 2 uM assessed by effect on rate of oxidation of S-mephenytoin 4'-hydroxylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID253550	Oral bioavailability in rat (dose 1 mg/kg)	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID254441	In vitro binding affinity for human histamine H3 receptor using [3H]N-alpha-methylhistamine	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID780098	Awakening activity in rat assessed as decrease of theta rhythm at 10 mg/kg, po after 3 to 4 hrs	2013	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 23, Issue:22	Discovery of a potent, selective, and orally bioavailable histamine H3 receptor antagonist SAR110068 for the treatment of sleep-wake disorders.
AID244056	Inhibition of CYP2C19 at 20 uM assessed by effect on rate of oxidation of S-mephenytoin 4'-hydroxylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244031	Inhibition of CYP1A2 at 2 uM assessed by effect on rate of oxidation of phenacetin O-deethylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID236100	Oral bioavailability in rat (dose 1-5 mg/kg i.v.)	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID246007	Tested for their ability to enhance memory in the adult rats using social recognition memory test	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244053	Inhibition of CYP2D6 at 2 uM assessed by effect on rate of oxidation of dextromethorphan O-demethylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID236104	Oral bioavailability in monkey (dose 1-5 mg/kg i.v.)	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID244044	Inhibition of CYP2E1 at 2 uM assessed by effect on rate of oxidation of chlorzoxazone 6-hydroxylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID692494	Binding affinity to human histamine H3 receptor	2011	Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1	Histamine H3 receptor as a drug discovery target.
AID253709	Maximum plasma concentration upon p.o. dose of 1 mg/kg in rats	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID611521	Systemic clearance in fasted Sprague-Dawley rat at 1 mg/kg, iv after 6 to 24 hrs by LC-MS/MS analysis	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist.
AID302565	Agonist activity at human histamine H3 receptor expressed in HEK239 cells assessed as reduction of basal [35S]GTP-gamma-S binding	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID302576	Protein binding in human plasma	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID253809	Terminal half life upon i.v. dose of 1 mg/kg in rats	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID254439	In vitro binding affinity for rat histamine H3 receptor using [3H]N-alpha-methylhistamine	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID244038	Inhibition of CYP3A4 at 20 uM assessed by effect on rate of oxidation of terfenadine hydroxylation upon incubation with human liver microsomes	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID305751	Volume of distribution in rat at terminal phase at 1 mg/kg, iv	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
AID239562	In vitro binding affinity was determined as displacement of [3H]N-R-methylhistamine from C6 cell membranes expressing rat histamine H3 receptor	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
AID253810	Terminal half life upon p.o. dose of 1 mg/kg in rats	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID483430	Displacement of [3H]N-alpha-methylhistamine from rat cloned histamine H3 receptor	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	In vitro studies on a class of quinoline containing histamine H3 antagonists.
AID302568	Volume of distribution in rat at 1 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis, potency, and in vivo profiles of quinoline containing histamine H3 receptor inverse agonists.
AID375418	Binding affinity to histamine H3 receptor	2009	Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13	5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity.
AID253576	Plasma clearance upon i.v. dose of 1 mg/kg in rats	2005	Journal of medicinal chemistry, Oct-06, Volume: 48, Issue:20	Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
AID483429	Displacement of [3H]N-alpha-methylhistamine from human cloned histamine H3 receptor	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	In vitro studies on a class of quinoline containing histamine H3 antagonists.
AID483432	Selectivity ratio of Ki for human cloned histamine H3 receptor over Ki for human ERG	2010	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11	In vitro studies on a class of quinoline containing histamine H3 antagonists.
AID1346037	Human H1 receptor (Histamine receptors)	2005	The Journal of pharmacology and experimental therapeutics, Apr, Volume: 313, Issue:1	Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
AID1346017	Rat H3 receptor (Histamine receptors)	2005	The Journal of pharmacology and experimental therapeutics, Apr, Volume: 313, Issue:1	Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
AID1346095	Human H2 receptor (Histamine receptors)	2005	The Journal of pharmacology and experimental therapeutics, Apr, Volume: 313, Issue:1	Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
AID1346107	Human H3 receptor (Histamine receptors)	2005	The Journal of pharmacology and experimental therapeutics, Apr, Volume: 313, Issue:1	Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	16 (48.48)	29.6817
2010's	15 (45.45)	24.3611
2020's	2 (6.06)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (2.94%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	33 (97.06%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
histamine [no description available]	2.76	3	aralkylamino compound; imidazoles	human metabolite; mouse metabolite; neurotransmitter
betahistine Betahistine: A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.. betahistine : An aminoalkylpyridine that is pyridine substituted by a 2-(methylamino)ethyl group at position 2. It acts as a histamine agonist and a vasodilator, and is thought to improve the microcirculation of the labyrinth, resulting in reduced endolymphatic pressure. It is used (generally as the hydrochloride or mesylate salt) to reduce the symptoms of vertigo, tinnitus, and hearing loss associated with Meniere's disease.	2.05	1	aminoalkylpyridine; secondary amino compound	H1-receptor agonist; vasodilator agent
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	2.1	1	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	2.13	1	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	2.44	2	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
alpha-methylhistamine alpha-methylhistamine: a histamine H3 receptor agonist; RN given refers to parent cpd without isomeric designation. alpha-methylhistamine : An aralkylamino compound that is histamine bearing a methyl substituent at the alpha-position.	2.04	1	aralkylamino compound; imidazoles	animal metabolite; H3-receptor agonist
imetit imetit: structure given in first source. imetit : An imidothiocarbamic ester that consists of isothiourea in which the thiol hydrogen is substituted by a 2-(imidazol-4-yl)ethyl group. An extremely potent, high affinity agonist at H3 and H4 receptors (Ki values are 0.3 and 2.7 nM respectively). Induces shape change in eosinophils with an EC50 of 25 nM. Centrally active following systemic administration.	3.16	1	imidazoles; imidothiocarbamic ester	H3-receptor agonist; H4-receptor agonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	2.02	1	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	2.02	1	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	2.05	1	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.05	1	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
kainic acid Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.	2.1	1	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	2.44	2	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.47	2	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
alpha-methylhistamine (R)-alpha-methylhistamine : An aralkylamino compound that is histamine bearing a methyl substituent at the alpha-position (the R-enantiomer).	2.05	1	aralkylamino compound; imidazoles	H3-receptor agonist
benzofurans Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.	4.06	14
interferon-gamma aplysamine-1: from sponge Aplysia sp.; structure in first source	2.05	1
conessine conessine : A steroid alkaloid that is con-5-enine substituted by a N,N-dimethylamino group at position 3. It has been isolated from the plant species of the family Apocynaceae.	2.05	1	steroid alkaloid; tertiary amino compound	antibacterial agent; antimalarial; H3-receptor antagonist; plant metabolite
jnj-5207852 [no description available]	4.24	5
4-(1h-imidazol-4-ylmethyl)piperidine 4-(1H-imidazol-4-ylmethyl)piperidine: structure in first source	3.16	1	piperidines
thioperamide thioperamide: structure given in first source; histamine H3 receptor antagonist	4.24	5	primary aliphatic amine
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione: a GSK3beta inhibitor. TDZD-8 : A member of the class of thiadiazolidines that is 1,2,4-thiadiazolidine-3,5-dione which is substituted by a methyl group at position 2 and by a benzyl group at position 4. It is a non-ATP competitive inhibitor of glycogen synthase kinase 3beta (GSK3beta). An experimental compound which was being developed for the potential treatment of Alzheimer's disease.	2.1	1	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
dizocilpine maleate Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.	2.05	1	maleate salt; tetracyclic antidepressant	anaesthetic; anticonvulsant; neuroprotective agent; nicotinic antagonist; NMDA receptor antagonist
ciproxifan [no description available]	3.14	5	aromatic ketone
gt 2331 [no description available]	3.16	1
nnc 38-1049 NNC 38-1049: selective histamine H3 receptor antagonist; structure in first source	3.56	2
dibutyl phthalate 6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide: GSK-189254 is the HCl salt; an H3 receptor antagonist; putative cognitive enhancer; structure in first source	4.07	4
a 304121 4-((3-(4-(2-aminopropanoyl)-1-piperazinyl)propoxy)phenyl)cyclopropylmethanone: InChIKey: GTMGELLVPUSBMG-UHFFFAOYSA-N	3.54	2
jnj 10181457 [no description available]	2.05	1
pitolisant pitolisant: functions as both inverse agonist and antagonist of histamine H3 receptors; structure in first source	2.96	4	organochlorine compound
a 317920 N-(2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxoethyl)-2-furamide: A-317920 is the (1R)-isomer; InChIKey: RTRADBQSZJIRMT-UHFFFAOYSA-N	3.54	2
mk-0249 MK-0249: a histamine-3 receptor inverse agonist; structure in first source	2.47	2
pf 03654746 [no description available]	3.16	1
gsk 1004723 GSK 1004723: structure in first source	3.16	1
cep 26401 [no description available]	2.47	2	pyridazines; ring assembly
piperidines Piperidines: A family of hexahydropyridines.	2.75	3
guanosine 5'-o-(3-thiotriphosphate) Guanosine 5'-O-(3-Thiotriphosphate): Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.	2.44	2	nucleoside triphosphate analogue
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	3.16	1	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	3.16	1	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor

Condition	Relationship Strength	Studies
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.02	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.05	1
Advanced Sleep Phase Syndrome [description not available]	2.08	1
Sleep Disorders, Circadian Rhythm Dyssomnias associated with disruption of the normal 24 hour sleep wake cycle secondary to travel (e.g., JET LAG SYNDROME), shift work, or other causes.	2.08	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.52	2
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Degenerative Diseases, Central Nervous System [description not available]	2.1	1
Absence Seizure [description not available]	2.1	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	2.1	1
Neurodegenerative Diseases Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.	2.1	1
Delayed Effects, Prenatal Exposure [description not available]	2.46	2
Alcohol Drinking Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.	2.05	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.46	2
Academic Disorder, Developmental [description not available]	2.05	1
Age-Related Memory Disorders [description not available]	2.05	1
Learning Disabilities Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.	2.05	1
Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.	2.05	1
Hyperactivity, Motor [description not available]	2.44	2
Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.	2.02	1
Dementia Praecox [description not available]	2.71	3
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	2.02	1
Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.	2.71	3
Cataleptic Attacks [description not available]	2.02	1

benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-

Cross-References

Synonyms (34)

Research Excerpts

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (27)

Molecular Functions (15)

Ceullar Components (8)

Bioassays (117)

Research

Studies (33)

Market Indicators

Research Demand Index: 10.86

Study Types

benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)-

Cross-References

Synonyms (34)

Research Excerpts

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (4)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (27)

Molecular Functions (15)

Ceullar Components (8)

Bioassays (117)

Research

Studies (33)

Market Indicators

Research Demand Index: 10.86

Study Types

Related Drugs (39)

Related Conditions (24)